date,title,source
Oct-18-18,Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China,GlobeNewswire
Nov-16-18,"Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China",GlobeNewswire
Nov-29-18,BRIEF-Innovent Biologics Enters Global Collaboration Agreement With Hutchison China Meditech,Reuters
Nov-29-18,Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors,GlobeNewswire
Dec-20-18,Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy,GlobeNewswire
Dec-20-18,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company,GlobeNewswire
Feb-08-19,Chi-Med to Announce 2018 Final Results,GlobeNewswire
Mar-11-19,Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs,GlobeNewswire
